医薬品安定保管サービスの世界市場：市場規模・シェア・動向分析 (サービス別・分子別・地域別・セグメント別、2025年～2030年)

医薬品安定保管サービス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の医薬品安定保管サービスの市場規模は、2025年から2030年にかけて6.48%のCAGRを記録し、2030年までに28億米ドルに達すると予測されています。

安定保管は様々な地域で必須の規制です。例えば、規制当局によって、安定性を試験するためのデータ要件や試験規則は異なります。FDAとEMAは安定性試験についてICHガイドラインに従っていますが、それでも安定性試験の微生物学的限界値は異なります。このため、安定性試験のアウトソーシングサービスに対する需要が向上し、市場に好影響を与える可能性が高いです。

COVID-19パンデミックはCOVID-19ワクチンの需要を世界的に増加させました。政府当局によるワクチン推進の高まりは、市販のCOVID-19ワクチンの安定性と保管に対する需要を促進すると思われます。近年、医薬品の研究開発費は大幅に改善しています。研究開発費の増加は、臨床段階にある医薬品の数を向上させると予想されます。臨床試験の各段階の承認には安定性試験が必要です。これが市場の成長をさらに後押ししています。さらに、バイオシミラー医薬品は生物学的製剤の高度に類似したコピーであり、生物学的製剤と比較して非常に安価です。

バイオシミラー医薬品は、がん、自己免疫疾患、その他の疾患に広く使用されています。このことがバイオシミラー医薬品の需要に寄与しており、市場の需要を牽引すると期待されています。COVID-19以降、いくつかの疾患が増加しています。例えば、Children's National Hospital-pediatric research and clinical innovations centerが発表した報告書によると、糖尿病と診断された737人の青少年を対象に調査が行われ、2018年3月11日から2021年3月10日の間に小児1型糖尿病 (T1D) の発症率が15.2%増加し、2型糖尿病 (T2D) が182%増加したことが分かりました。疾患罹患率の上昇は、医薬品生産を改善し、市場需要を促進すると予想されます。

医薬品安定保管サービス市場：分析概要

• 安定性試験サービス分野は、2024年に73.5%のシェアを占め、医薬品安定・保管業界を支配しました。同分野の成長は主に、規制遵守、製品の安全性、有効性における重要な役割によるものです。
• 2024年のサービス市場は、低分子セグメントが支配的でした。低分子医薬品の開発には著しい進歩が見られます。
• 北米の医薬品安定保管サービス市場が市場を席巻し、2024年のシェアは40.0%に達しました。同地域の成長は、複数の製薬企業やバイオテクノロジー企業が同地域に存在すること、研究開発活動の活発化が同地域の市場成長を牽引していることによります。
• アジア太平洋地域の医薬品安定保管サービス市場は、予測期間中に最も高いCAGRで成長すると予想されます。アジア太平洋地域は、患者数が多く多様性に富み、規制環境も良好であることから、臨床試験の主要な中心地となりつつあります。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 医薬品安定保管サービス市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 安定・保管のコスト構造
• 医薬品安定保管サービス市場：分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
• COVID-19の影響分析

第4章 医薬品安定保管サービス市場：サービス別の推定と動向分析

• セグメントダッシュボード
• 世界の医薬品安定保管サービス市場：サービス別の変動分析
• 世界の医薬品安定保管サービス市場：市場規模の予測と動向分析、サービス別 (2018～2030年)
• 安定性
  • 薬物成分
  • 安定性の表示方法の検証
  • 加速安定性試験
  • 光安定性試験
  • その他の安定性試験方法
• 保管
  • 冷蔵
  • 非冷蔵

第5章 医薬品安定保管サービス市場：分子別の推定・動向分析

• セグメントダッシュボード
• 世界の医薬品安定保管サービス市場：分子別の変動分析
• 世界の医薬品安定保管サービス市場：市場規模の予測と動向分析、分子別 (2018～2030年)
• 低分子
  • 研究用製品
  • 商用製品
• 高分子
  • 研究用製品
  • 商用製品

第6章 医薬品安定保管サービス市場：地域別の推定・動向分析

• 市場シェア分析：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業分類
• 企業の市場ポジション分析 (2024年)
• 企業プロファイル
  • Catalent, Inc
  • Almac Group
  • Charles River Laboratories
  • SGS Societe Generale de Surveillance SA.
  • Eurofins Scientific
  • Intertek Group plc
  • Lucideon Limited
  • Alcami Corporation
  • Element Materials Technology
  • BioLife Solutions Inc.
  • Q1 Scientific
  • Reading Scientific Services Ltd.
  • Roylance Stability Storage Limited
  • ALS
  • Q Laboratories
  • Auriga Research Private Limited
  • PD Partners
  • Precision Stability Storage

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 4 Global Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 5 Global Pharmaceutical Stability & Storage Services, by Region, 2018 - 2030 (USD Million)
• Table 6 North America Pharmaceutical Stability & Storage Services, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 8 North America Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 9 U.S. Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 10 U.S. Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 11 Canada Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 12 Canada Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 13 Mexico Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 14 Mexico Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 15 UK Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 16 UK Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 17 Germany Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 18 Germany Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 19 France Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 20 France Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 21 Italy Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 22 Italy Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 23 Spain Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 24 Spain Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 25 Sweden Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 26 Sweden Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 27 Norway Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 28 Norway Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 29 Denmark Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 30 Denmark Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 31 India Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 32 India Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 33 China Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 34 China Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 35 Japan Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 36 Japan Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 37 India Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 38 India Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 39 Australia Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 40 Australia Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 41 Thailand Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 42 Thailand Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 43 South Korea Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 44 South Korea Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 45 Brazil Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 46 Brazil Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 47 Argentina Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 48 Argentina Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 49 Saudi Arabia Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 50 Saudi Arabia Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 51 UAE Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 52 UAE Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)
• Table 53 Kuwait Pharmaceutical Stability & Storage Services, by Service, 2018 - 2030 (USD Million)
• Table 54 Kuwait Pharmaceutical Stability & Storage Services, by Molecule, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Pharmaceutical Stability & Storage Services, Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 Porter's Five Forces Analysis
• Fig. 10 PESTEL Analysis
• Fig. 11 Regional Marketplace: Key Takeaways
• Fig. 12 Global Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 13 Global Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 14 Global Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 15 Global pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 16 Global Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 17 Global Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 18 Global Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 19 Global Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 20 Global Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 21 Global Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 22 Global Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 23 Global Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 24 Global Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 25 North America Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 26 North America Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 27 North America Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 28 North America Pharmaceutical Stability Services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 29 North America Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 30 North America Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 31 North America Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 32 North America Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 33 North America Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 34 North America Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 35 North America Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 36 North America Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 37 North America Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 38 U.S. Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 39 U.S. Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 40 U.S. Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 41 U.S. pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 42 U.S. Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 43 U.S. Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 44 U.S. Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 45 U.S. Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 46 U.S. Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 47 U.S. Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 48 U.S. Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 49 U.S. Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 50 U.S. Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 51 Canada Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 52 Canada Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 53 Canada Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 54 Canada pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 55 Canada Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 56 Canada Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 57 Canada Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 58 Canada Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 59 Canada Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 60 Canada Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 61 Canada Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 62 Canada Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 63 Canada Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 64 Mexico Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 65 Mexico Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 66 Mexico Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 67 Mexico pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 68 Mexico Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 69 Mexico Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 70 Mexico Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 71 Mexico Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 72 Mexico Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 73 Mexico Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 74 Mexico Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 75 Mexico Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 76 Mexico Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 77 Europe Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 78 Europe Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 79 Europe Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 80 Europe pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 81 Europe Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 82 Europe Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 83 Europe Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 84 Europe Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 85 Europe Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 86 Europe Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 87 Europe Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 88 Europe Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 89 Europe Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 90 UK Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 91 UK Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 92 UK Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 93 UK pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 94 UK Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 95 UK Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 96 UK Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 97 UK Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 98 UK Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 99 UK Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 100 UK Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 101 UK Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 102 UK Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 103 Germany Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 104 Germany Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 105 Germany Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 106 Germany pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 107 Germany Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 108 Germany Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 109 Germany Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 110 Germany Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 111 Germany Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 112 Germany Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 113 Germany Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 114 Germany Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 115 Germany Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 116 France Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 117 France Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 118 France Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 119 France pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 120 France Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 121 France Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 122 France Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 123 France Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 124 France Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 125 France Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 126 France Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 127 France Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 128 France Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 129 Italy Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 130 Italy Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 131 Italy Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 132 Italy pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 133 Italy Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 134 Italy Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 135 Italy Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 136 Italy Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 137 Italy Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 138 Italy Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 139 Italy Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 140 Italy Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 141 Italy Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 142 Spain Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 143 Spain Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 144 Spain Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 145 Spain pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 146 Spain Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 147 Spain Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 148 Spain Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 149 Spain Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 150 Spain Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 151 Spain Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 152 Spain Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 153 Spain Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 154 Spain Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 155 Denmark Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 156 Denmark Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 157 Denmark Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 158 Denmark pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 159 Denmark Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 160 Denmark Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 161 Denmark Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 162 Denmark Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 163 Denmark Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 164 Denmark Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 165 Denmark Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 166 Denmark Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 167 Denmark Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 168 Sweden Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 169 Sweden Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 170 Sweden Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 171 Sweden pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 172 Sweden Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 173 Sweden Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 174 Sweden Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 175 Sweden Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 176 Sweden Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 177 Sweden Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 178 Sweden Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 179 Sweden Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 180 Sweden Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 181 Norway Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 182 Norway Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 183 Norway Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 184 Norway pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 185 Norway Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 186 Norway Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 187 Norway Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 188 Norway Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 189 Norway Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 190 Norway Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 191 Norway Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 192 Norway Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 193 Norway Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 194 Asia Pacific Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 195 Asia Pacific Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 196 Asia Pacific Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 197 Asia Pacific pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 198 Asia Pacific Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 199 Asia Pacific Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 200 Asia Pacific Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 201 Asia Pacific Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 202 Asia Pacific Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 203 Asia Pacific Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 204 Asia Pacific Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 205 Asia Pacific Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 206 Asia Pacific Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 207 Japan Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 208 Japan Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 209 Japan Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 210 Japan pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 211 Japan Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 212 Japan Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 213 Japan Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 214 Japan Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 215 Japan Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 216 Japan Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 217 Japan Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 218 Japan Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 219 Japan Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 220 China Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 221 China Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 222 China Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 223 China pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 224 China Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 225 China Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 226 China Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 227 China Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 228 China Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 229 China Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 230 China Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 231 China Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 232 China Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 233 India Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 234 India Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 235 India Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 236 India pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 237 India Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 238 India Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 239 India Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 240 India Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 241 India Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 242 India Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 243 India Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 244 India Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 245 India Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 246 Australia Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 247 Australia Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 248 Australia Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 249 Australia pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 250 Australia Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 251 Australia Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 252 Australia Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 253 Australia Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 254 Australia Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 255 Australia Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 256 Australia Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 257 Australia Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 258 Australia Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 259 South Korea Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 260 South Korea Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 261 South Korea Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 262 South Korea pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 263 South Korea Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 264 South Korea Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 265 South Korea Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 266 South Korea Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 267 South Korea Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 268 South Korea Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 269 South Korea Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 270 South Korea Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 271 South Korea Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 272 Thailand Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 273 Thailand Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 274 Thailand Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 275 Thailand pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 276 Thailand Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 277 Thailand Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 278 Thailand Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 279 Thailand Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 280 Thailand Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 281 Thailand Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 282 Thailand Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 283 Thailand Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 284 Thailand Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 285 Latin America Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 286 Latin America Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 287 Latin America Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 288 Latin America pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 289 Latin America Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 290 Latin America Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 291 Latin America Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 292 Latin America Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 293 Latin America Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 294 Latin America Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 295 Latin America Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 296 Latin America Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 297 Latin America Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 298 Brazil Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 299 Brazil Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 300 Brazil Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 301 Brazil pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
• Fig. 302 Brazil Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
• Fig. 303 Brazil Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
• Fig. 304 Brazil Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
• Fig. 305 Brazil Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
• Fig. 306 Brazil Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
• Fig. 307 Brazil Small Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 308 Brazil Small Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 309 Brazil Large Molecule Pharmaceutical Stability & Storage Services, for Research Products, 2018 - 2030 (USD Million)
• Fig. 310 Brazil Large Molecule Pharmaceutical Stability & Storage Services, for Commercial Products
• Fig. 311 Argentina Pharmaceutical Stability & Storage Services, for Service, 2018 - 2030 (USD Million)
• Fig. 312 Argentina Pharmaceutical Stability & Storage Services, for Stability, 2018 - 2030 (USD Million)
• Fig. 313 Argentina Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 314 Argentina pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)

Pharmaceutical Stability And Storage Services Market Growth & Trends:

The global pharmaceutical stability and storage services market size is expected to reach USD 2.80 billion by 2030, registering a CAGR of 6.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. Stability and storage is a mandatory regulation in various regions. For instance, different regulatory authorities have different data requirements and testing rules for testing stability. Even though FDA and EMA follow the ICH guidelines for stability testing, they still have different microbiological limits for stability tests. This has improved the demand for stability testing outsourcing services and is likely to have a positive impact on the market.

The COVID-19 pandemic had increased the demand for COVID-19 vaccines globally. The growing vaccine drive by the government authorities is likely to drive the demand for stability and storage of commercial COVID-19 vaccines. In recent years pharmaceutical R&D spending has improved significantly. The growing R&D spending is expected to improve the number of drugs in the clinical stage. Stability testing is required for the approval of each phase of a clinical trial. This is further driving the market growth. Moreover, Biosimilar drugs are highly similar copies of biologics and are very cheaper, as compared to biologics.

Biosimilar drugs are widely used in cancer, autoimmune diseases, and other diseases. This is contributing to the demand for biosimilar drugs and thereby is expected to drive the market demand. There has been a rise in several diseases post-COVID-19. For instance, according to a report published by Children's National Hospital- pediatric research and clinical innovations center, a study was performed on 737 youths who were diagnosed with diabetes, and it found an increased incidence of pediatric Type 1 Diabetes (T1D) by 15.2% and Type 2 Diabetes (T2D) increased by 182% between March 11, 2018, and March 10, 2021. The rise in the disease incidence is expected to improve, drug production, which is likely to drive the market demand.

Pharmaceutical Stability And Storage Services Market Report Highlights:

• Stability testing services segment dominated the pharmaceutical stability and storage industry with a share of 73.5% in 2024. The growth of the segment is mainly due to its important role in regulatory compliance, product safety, and efficacy.
• Small molecule segment dominated the services market in 2024. There have been significant advancements in small molecule drug development.
• North America pharmaceutical stability and storage services market dominated the market and accounted for a 40.0% share in 2024. The growth in the region is attributed to the presence of several pharmaceutical and biotech companies in the region, coupled with increasing research and development activities are driving the regions market growth.
• Asia Pacific pharmaceutical stability & storage services market is expected to grow at the highest CAGR over the forecast period. Asia Pacific is becoming a major center for clinical trials due to its large and diverse patient population and favorable regulatory environments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Pharmaceutical Stability & Storage Services Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High R&D Spending of Pharmaceutical & Biotechnology Companies
    • 3.2.1.2. Growing Demand for Outsourcing Stability Testing Due to High Complexity Associated with Drug Stability
    • 3.2.1.3. Growing Demand for Biosimilars
    • 3.2.1.4. Growing Outsourcing Trend in the Market
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Strict Regulations for Global Pharmaceutical Stability and Storage Services Drugs
    • 3.2.2.2. Issues Associated with Stability Chambers
• 3.3. Cost Structure of Stability and Storage
• 3.4. Pharmaceutical Stability & Storage Services Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL Analysis
• 3.5. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Stability & Storage Services Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Pharmaceutical Stability & Storage Services Market; Service Movement Analysis
• 4.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Stability
  • 4.4.1. Stability market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Drug Substance
    • 4.4.2.1. Drug substance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Stability Indicating Method Validation
    • 4.4.3.1. Stability indicating method validation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Accelerated Stability Testing
    • 4.4.4.1. Accelerated stability testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Photostability Testing
    • 4.4.5.1. Photostability testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Other Stability Testing Methods
    • 4.4.6.1. Other stability testing methods market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Storage
  • 4.5.1. Storage market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Cold
    • 4.5.2.1. Cold market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Non-cold
    • 4.5.3.1. Non-cold market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Stability & Storage Services Market: Molecule Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Pharmaceutical Stability & Storage Services Market; Molecule Movement Analysis
• 5.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
• 5.4. Small Molecule
  • 5.4.1. Small molecule market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Research Products
    • 5.4.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Commercial Products
    • 5.4.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Large Molecule
  • 5.5.1. Large molecule market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Research Products
    • 5.5.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Commercial Products
    • 5.5.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Stability & Storage Services Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Competitive scenario
    • 6.5.8.3. Regulatory framework
    • 6.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key country dynamics
    • 6.5.9.2. Competitive scenario
    • 6.5.9.3. Regulatory framework
    • 6.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Competitive scenario
    • 6.6.4.3. Regulatory framework
    • 6.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Competitive scenario
    • 6.6.5.3. Regulatory framework
    • 6.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Competitive scenario
    • 6.6.6.3. Regulatory framework
    • 6.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Competitive scenario
    • 6.6.7.3. Regulatory framework
    • 6.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Competitive scenario
    • 6.8.2.3. Regulatory framework
    • 6.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Competitive scenario
    • 6.8.3.3. Regulatory framework
    • 6.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Competitive scenario
    • 6.8.4.3. Regulatory framework
    • 6.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key country dynamics
    • 6.8.5.2. Competitive scenario
    • 6.8.5.3. Regulatory framework
    • 6.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Position Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. Catalent, Inc
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Service benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Almac Group
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Service benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Charles River Laboratories
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Service benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. SGS Societe Generale de Surveillance SA.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Service benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Eurofins Scientific
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Service benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Intertek Group plc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Service benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Lucideon Limited
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Service benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Alcami Corporation
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Service benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Element Materials Technology
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Service benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. BioLife Solutions Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Service benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Q1 Scientific
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Service benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Reading Scientific Services Ltd.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Service benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Roylance Stability Storage Limited
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Service benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. ALS
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Service benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Q Laboratories
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Service benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Auriga Research Private Limited
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Service benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. PD Partners
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Service benchmarking
    • 7.3.17.4. Strategic initiatives
  • 7.3.18. Precision Stability Storage
    • 7.3.18.1. Company overview
    • 7.3.18.2. Financial performance
    • 7.3.18.3. Service benchmarking
    • 7.3.18.4. Strategic initiatives